Article: Sirolimus in kidney transplantation: A pilot study in Chinese patients

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleSirolimus in kidney transplantation: A pilot study in Chinese patients
AuthorsLam, MF1
Yip, TPS1
Tse, KC1
Li, FK1
Lui, SL1
Lai, KN1
Chan, TM1
KeywordsChinese population
Hyperlipidemia
Kidney transplantation
Sirolimus
Issue Date2004
PublisherLippincott Williams & Wilkins Asia. The Journal's web site is located at http://www.hkjn.org/
CitationHong Kong Journal Of Nephrology, 2004, v. 6 n. 1, p. 38-42 [How to Cite?]
AbstractWe conducted a pilot open-label study on the use of sirolimus in 10 Chinese patients undergoing kidney transplantation who received triple prophylactic immunosuppression comprising prednisolone, cyclosporine and sirolimus. Sirolimus was given as a 6 mg loading dose followed by 2 mg/day maintenance. All patients achieved target sirolimus trough serum concentrations exceeding 5 ng/mL. Median duration of follow-up was 22 months after transplantation. One patient developed Type Ia acute cellular rejection at 6 months, which responded to pulse steroid therapy. Graft survival was 100% at 12 months and serum creatinine was 131 ± 36 μmol/L at 1 year. Low-density lipoprotein cholesterol and triglyceride levels were significantly increased after 2 months. Eight patients received atorvastatin, which was subsequently discontinued successfully in three patients. Infection was noted in two patients; one died of pneumocystis pneumonia 10 months after transplantation and the other had septicemia from urinary tract infection complicating graft vesicoureteric reflux. Two patients developed lymphocele in the early postoperative period, which resolved spontaneously in one patient and was treated successfully with ethanol sclerotherapy in the other. No patients developed thrombocytopenia or arthralgia. We conclude that sirolimus, when used together with prednisolone and cyclosporine, is well tolerated and effective in Chinese renal allograft recipients, and that hyperlipidemia early after transplantation is the most common adverse effect.
ISSN1561-5413
2011 SCImago Journal Rankings: 0.031
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLam, MF
dc.contributor.authorYip, TPS
dc.contributor.authorTse, KC
dc.contributor.authorLi, FK
dc.contributor.authorLui, SL
dc.contributor.authorLai, KN
dc.contributor.authorChan, TM
dc.date.accessioned2010-09-06T07:30:29Z
dc.date.available2010-09-06T07:30:29Z
dc.date.issued2004
dc.description.abstractWe conducted a pilot open-label study on the use of sirolimus in 10 Chinese patients undergoing kidney transplantation who received triple prophylactic immunosuppression comprising prednisolone, cyclosporine and sirolimus. Sirolimus was given as a 6 mg loading dose followed by 2 mg/day maintenance. All patients achieved target sirolimus trough serum concentrations exceeding 5 ng/mL. Median duration of follow-up was 22 months after transplantation. One patient developed Type Ia acute cellular rejection at 6 months, which responded to pulse steroid therapy. Graft survival was 100% at 12 months and serum creatinine was 131 ± 36 μmol/L at 1 year. Low-density lipoprotein cholesterol and triglyceride levels were significantly increased after 2 months. Eight patients received atorvastatin, which was subsequently discontinued successfully in three patients. Infection was noted in two patients; one died of pneumocystis pneumonia 10 months after transplantation and the other had septicemia from urinary tract infection complicating graft vesicoureteric reflux. Two patients developed lymphocele in the early postoperative period, which resolved spontaneously in one patient and was treated successfully with ethanol sclerotherapy in the other. No patients developed thrombocytopenia or arthralgia. We conclude that sirolimus, when used together with prednisolone and cyclosporine, is well tolerated and effective in Chinese renal allograft recipients, and that hyperlipidemia early after transplantation is the most common adverse effect.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationHong Kong Journal Of Nephrology, 2004, v. 6 n. 1, p. 38-42 [How to Cite?]
dc.identifier.epage42
dc.identifier.hkuros99092
dc.identifier.issn1561-5413
2011 SCImago Journal Rankings: 0.031
dc.identifier.issue1
dc.identifier.openurl
dc.identifier.scopuseid_2-s2.0-2342623354
dc.identifier.spage38
dc.identifier.urihttp://hdl.handle.net/10722/77307
dc.identifier.volume6
dc.languageeng
dc.publisherLippincott Williams & Wilkins Asia. The Journal's web site is located at http://www.hkjn.org/
dc.publisher.placeHong Kong
dc.relation.ispartofHong Kong Journal of Nephrology
dc.relation.referencesReferences in Scopus
dc.subjectChinese population
dc.subjectHyperlipidemia
dc.subjectKidney transplantation
dc.subjectSirolimus
dc.titleSirolimus in kidney transplantation: A pilot study in Chinese patients
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong